J Korean Med Sci.  2005 Oct;20(5):853-859. 10.3346/jkms.2005.20.5.853.

Immunoexpression of HBME-1, High Molecular Weight Cytokeratin, Cytokeratin 19, Thyroid Transcription Factor-1, and E-cadherin in Thyroid Carcinomas

• Choi YL
• Kim MK
• Suh JW
• Han J
• Kim JH
• Yang JH
• Nam SJ

• KMID: 1781771
• DOI: http://doi.org/10.3346/jkms.2005.20.5.853

Abstract

To examine the immunohistochemical alterations associated with the histological dedifferentiation of thyroid carcinomas, we performed staining for HBME-1, high molecular weight cytokeratin (HCK), CK 19, thyroid transcription factor-1 (TTF-1) and E-cadherin (E-CD) on 125 various types of thyroid carcinomas. The HBME-1 staining was strong and diffuse in follicular carcinoma (FC), papillary carcinoma (PC), and poorly differentiated carcinoma (PDC), while it was rare in undifferentiated carcinoma (UC) as well as in benign lesions. Strong, diffuse staining for CK19 and HCK was predominantly found in PC, and these markers were not much found in other carcinomas. TTF-1 uniformly stained the tumor cells of all cases of PC, FC and Hurthle cell carcinoma (HC) and 42% of the PDC, while there was only focal staining in one case of the UC. Compared to the strong, diffuse reactivity in the benign lesions, E-CD staining was noted in 67% of PC, 80% of FC, 83% of HC, 58% of PDC and none of the UC. These results suggest that HBME-1 may be a marker for well-differentiated carcinomas while CK19 and HCK are phenotypic markers for papillary carcinoma. The loss or reduced expression of TTF-1 and E-CD may be markers for dedifferentiation.

Keyword

HBME-1 antigen; Keratin; thyroid nuclear factor 1; Cadherins; Thyroid Neoplasms

MeSH Terms

Cadherins/*metabolism
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Keratin/*metabolism
Nuclear Proteins/*metabolism
Research Support, Non-U.S. Gov't
Thyroid Neoplasms/*metabolism
Transcription Factors/*metabolism
Tumor Markers, Biological/*metabolism

Figure

• 

  Fig. 1 Expression of HBME-1 in thyroid carcinomas: (A) undifferentiated thyroid carcinoma showing scattered reactivity (×100), (B) papillary carcinoma (×200) and (C) follicular carcinoma with diffuse reactivity (×100).

• 

  Fig. 2 Expression of HCK: (A) undifferentiated carcinoma of squamoid type showing strong reactivity (×200), (B) undifferentiated carcinoma of giant cell type showing non-reactivity (×200) and (C) papillary carcinoma with focal reactivity (×100).

• 

  Fig. 3 Expression of TTF-1 in thyroid lesions: (A) undifferentiated thyroid carcinoma showing focal reactivity in several tumor cells (arrows), in contrast to diffuse reactivity in entrapped follicular epithelial cells (×200); (B) diffuse and strong reactivity in poorly differentiated carcinoma (×200) and (C) follicular adenoma showing diffuse reactivity (×100).

• 

  Fig. 4 Loss of expression of E-CD in (A) undifferentiated carcinoma (×200) and (B) papillary carcinoma (×200).

Reference

1. Rosai J. Rosai J, editor. Thyroid gland. Rosai and Ackermann's Surgical Pathology. 2004. 9 ed. Phildelphia: Elsevier;515–594.

2. van Hoeven KH, Kovatich AJ, Miettinen M. Immunocytochemical evaluation of HBME-1, CA 19-9, and CD-15 (Leu-M1) in fine-needle aspirates of thyroid nodules. Diagn Cytopathol. 1998. 18:93–97.

3. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol. 2003. 14:55–60.

4. Sack MJ, Astengo-Osuna C, Lin BT, Battifora H, LiVolsi VA. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol. 1997. 10:668–674.

5. Cameron BR, Berean KW. Cytokeratin subtypes in thyroid tumors: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma. J Otolaryngol. 2003. 32:319–322.

6. Kragsterman B, Grimelius L, Wallin G, Werga P, Johansson H. Cytokeratin 19 expression in papillary thyroid carcinoma. Appl Immunohistochem Mol Morphol. 1999. 7:181–185.

7. Shin E, Chung WY, Yang WI, Park CS, Hong SW. RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation. J Korean Med Sci. 2005. 20:98–104.

8. Baloch ZW, Abraham S, Roberts S, LiVolsi VA. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility. Hum Pathol. 1999. 30:1166–1171.

9. Liberman E, Weidner N. Papillary and follicular neoplasms of the thyroid gland. Differential immunohistochemical staining with high-molecular-weight keratin and involucrin. Appl Immunohistochem Mol Morphol. 2000. 8:42–48.

10. Yap AS, Stevenson BR, Keast JR, Manley SW. Cadherin-mediated adhesion and apical membrane assembly define distinct steps during thyroid epithelial polarization and lumen formation. Endocrinology. 1995. 136:4672–4680.

11. Brabant G, Hoang-Vu C, Behrends J, Cetin Y, Potter E, Dumont JE, Maenhaut C. Regulation of the cell-cell adhesion protein, E-cadherin, in dog and human thyrocytes in vitro. Endocrinology. 1995. 136:3113–3119.

12. Brabant G, Hoang-Vu C, Cetin Y, Dralle H, Scheumann G, Molne J, Hansson G, Jansson S, Ericson LE, Nilsson M. E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res. 1993. 53:4987–4993.

13. Soares P, Berx G, van Roy F, Sobrinho-Simoes M. E-cadherin gene alterations are rare events in thyroid tumors. Int J Cancer. 1997. 70:32–38.

14. Scheumman GF, Hoang-Vu C, Cetin Y, Gimm O, Behrends J, von Wasielewski R, Georgii A, Birchmeier W, von Zur Muhlen A, Dralle H. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J Clin Endocrinol Metab. 1995. 80:2168–2172.

15. Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira MC, Sobrinho-Simoes M. E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology. 2003. 42:580–587.

16. von Wasielewski R, Rhein A, Werner M, Scheumann GF, Dralle H, Potter E, Brabant G, Georgii A. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res. 1997. 57:2501–2507.

17. Rosia J, Carcangiu ML, Delellis RA. Atlas of Tumor Pathology: Tumors of the thyroid gland. AFIP third series, fascicle 5. 1992.

18. LiVolsi VA. Saunders , editor. Surgical pathology of the thyroid. 1990. Philadelphia, PA:

19. Cerrato A, Fulciniti F, Avallone A, Benincasa G, Palombini L, Grieco M. Beta- and gamma-catenin expression in thyroid carcinomas. J Pathol. 1998. 185:267–272.

20. Graff JR, Greenberg VE, Herman JG, Westra WH, Boghaert ER, Ain KB, Saji M, Zeiger MA, Zimmer SG, Baylin SB. Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res. 1998. 58:2063–2066.

21. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999. 59:1811–1815.

22. Lonigro R, De Felice M, Biffali E, Macchia PE, Damante G, Asteria C, Di Lauro R. Expression of thyroid transcription factor 1 gene can be regulated at the transcriptional and posttranscriptional levels. Cell Growth Differ. 1996. 7:251–261.

23. Katoh R, Kawaoi A, Miyagi E, Li X, Suzuki K, Nakamura Y, Kakudo K. Thyroid transcription factor-1 in normal, hyperplastic, and neoplastic follicular thyroid cells examined by immunohistochemistry and nonradioactive in situ hybridization. Mod Pathol. 2000. 13:570–576.